HC Wainwright Forecasts Stronger Earnings for Pharming Group

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) – Stock analysts at HC Wainwright lifted their FY2025 earnings per share (EPS) estimates for shares of Pharming Group in a research note issued to investors on Thursday, November 6th. HC Wainwright analyst J. Pantginis now anticipates that the company will earn $0.02 per share for the year, up from their prior estimate of ($0.20). The consensus estimate for Pharming Group’s current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Pharming Group’s Q4 2025 earnings at $0.05 EPS.

Pharming Group (NASDAQ:PHAR) last posted its earnings results on Thursday, November 6th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.05. The firm had revenue of $97.30 million during the quarter, compared to analysts’ expectations of $98.22 million. Pharming Group had a return on equity of 0.46% and a net margin of 0.30%. Pharming Group has set its FY 2025 guidance at EPS.

PHAR has been the subject of a number of other reports. Zacks Research raised shares of Pharming Group from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 6th. Weiss Ratings downgraded Pharming Group from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Pharming Group has a consensus rating of “Moderate Buy” and an average target price of $30.00.

Pharming Group Stock Up 13.7%

Shares of NASDAQ:PHAR opened at $17.55 on Monday. The company has a current ratio of 3.16, a quick ratio of 2.39 and a debt-to-equity ratio of 0.35. Pharming Group has a twelve month low of $7.31 and a twelve month high of $17.76. The company has a market capitalization of $1.20 billion, a PE ratio of -1,753.25 and a beta of 0.03. The firm has a 50 day simple moving average of $14.36 and a 200-day simple moving average of $12.12.

Institutional Trading of Pharming Group

An institutional investor recently bought a new position in Pharming Group stock. EverSource Wealth Advisors LLC purchased a new position in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 2,979 shares of the company’s stock, valued at approximately $32,000. Institutional investors own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.